Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-062 manufacturers

Filters

1 products found

pp-062

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Pancreatic cancer, particularly patients with advanced or metastatic disease requiring immune-modulating combination strategies. Clinical stage: Phase 1b clinical development. Modality: Immuno-oncology combination therapy (details of component agents not publicly disclosed). Mechanism / Target: Designed to modulate tumor-immune interactions and enhance antitumor responses in poorly immunogenic pancreatic tumors; incorporates synergy between immunotherapeutic and tumor-targeting pathways. Route / form: Systemic administration (formulation not publicly disclosed). Differentiation: Targets the highly treatment-resistant pancreatic tumor microenvironment using a multi-mechanism immuno-oncology strategy; aims to improve responsiveness in a cancer type with limited benefit from standard immunotherapies.
Manufacturer #38615

A clinical-stage biotech firm developing next-generation nucleotide and small-molecule therapies targeting cancer and other unmet medical needs. It combines proprietary ASO and drug discovery platforms with global development and strategic partnership goals. The organization advances multiple early- to mid-stage programs through clinical and preclinical research.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.